Clinical Trial · NCT05655949

A Single Arm Phase 2 Study of Y-90 SIRT in Combination With Durvalumab (MEDI 4736) and Gemcitabine/Cisplatin in Locally Advanced, Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Overview

This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery. The specific names of the interventions that will be used are: Y-90 (a type of radiation microsphere bead) Durvalumab (a type of immunotherapy) Gemcitabine (a type of chemotherapy) Cisplatin (a type of chemotherapy)

Sponsor

Beth Israel Deaconess Medical Center

Phase

Phase 2

Contacts

Andrea Bullock, MD, MPH (Principal Investigator)

abullock@bidmc.harvard.edu

617-667-2100

Victoria Weden, BS

vweden@bidmc.harvard.edu

617-667-2100

ClinicalTrials.gov

NCT05655949

Drug / Compound

Isotope(s):

Target(s):